Hostname: page-component-76d6cb85b7-xh428 Total loading time: 0 Render date: 2026-07-15T15:49:35.772Z Has data issue: false hasContentIssue false
  • English
  • Français

Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?

Part of: Biological Basis of Mental Disorders and their Treatment Understanding and Treating Mood and Anxiety Disorders

Published online by Cambridge University Press:  29 January 2026

Andy Lu Open the ORCID record for Andy Lu [Opens in a new window] ,
Heidi Xu Open the ORCID record for Heidi Xu [Opens in a new window] ,
Gia Han Le Open the ORCID record for Gia Han Le [Opens in a new window] ,
Christine E. Dri ,
Sabrina Wong Open the ORCID record for Sabrina Wong [Opens in a new window] ,
Roger Ho ,
Bing Cao Open the ORCID record for Bing Cao [Opens in a new window] ,
Heidi Ka Ying Lo Open the ORCID record for Heidi Ka Ying Lo [Opens in a new window] ,
Taeho Greg Rhee Open the ORCID record for Taeho Greg Rhee [Opens in a new window]  and
Liyang Yin
...Show all authors
Andy Lu
Affiliation:
Department of Psychology, University of Western Ontario, London, ON, Canada Brain and Cognition Discovery Foundation, Toronto, ON, Canada
Heidi Xu
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada Department of Toxicology and Neuroscience, University of Toronto, Toronto, ON, Canada
Gia Han Le
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada Institute of Medical Science, University of Toronto, Toronto, ON, Canada Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada
Christine E. Dri
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada
Sabrina Wong
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
Roger Ho
Affiliation:
Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore Division of Life Science (LIFS), Hong Kong University of Science and Technology (HKUST), Clear Water Bay, Hong Kong.
Bing Cao
Affiliation:
Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing, 400715, P. R. China
Heidi Ka Ying Lo
Affiliation:
Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong
Taeho Greg Rhee
Affiliation:
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA
Liyang Yin
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada
Hernan F. Guillen-Burgos
Affiliation:
Pontificia Universidad Javeriana, Department of Psychiatry and Mental Health, Bogota DC, Colombia Center for Clinical and Translational Research, Bogota DC, Colombia Universidad Simón Bolívar, Center for Clinical and Translational Research, Barranquilla, Colombia
Roger S. McIntyre*
Affiliation:
Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
*
Corresponding author: Roger S. McIntyre; Email: roger.mcintyre@bcdf.org

Abstract

Background

Ketamine and esketamine produce rapid and sustained antidepressant effects in persons with treatment-resistant depression (TRD). Although it is posited that these effects are largely attributed to N-methyl-D-aspartate receptor antagonism, the potential involvement of the opioid system remains unclear. This systematic review investigates whether ketamine and esketamine antidepressant efficacy is mediated through the opioid system.

Methods

We conducted a systematic search of preclinical and clinical studies investigating the potential involvement of the opioid system in the antidepressant effects of ketamine and esketamine. Database searches on PubMed, Cochrane Library, Embase and PsycINFO occurred from inception to September 27, 2025.

Results

16 studies were identified: 12 clinical (n = 790) and 4 preclinical studies. Clinical designs included randomized controlled trials, case reports, pre-post studies and observational cohort studies. Preclinical studies utilized animal models of depression. Only one study examined esketamine. Naltrexone (nonselective opioid antagonist) attenuated ketamine’s effects in three studies, while four reported no such effect and one reported mixed evidence. Genetic markers of opioid receptor subtypes (i.e., OPRM1 and OPRD1) were examined in three studies, but results were inconclusive, potentially due to limited evidence. Separately, opioid use was not associated with ketamine response. Few studies directly examined opioid receptor subtypes.

Conclusions

The reported mixed findings suggest that the opioid system may exert a partial mediating effect of ketamine in TRD. However, given the inconsistent attenuation of ketamine’s antidepressant effects by opioid receptor antagonists, the opioid system likely functions as a context-dependent modulator rather than a primary mediator, particularly at standard antidepressant doses.

Keywords

ketamineesketaminereceptorsopioiddepressive disordertreatment-resistantmajor

Information

Type
Review/Meta-analysis
Information
European Psychiatry , Volume 69 , Issue 1 , 2026 , e24
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of European Psychiatric Association

Introduction

Major depressive disorder (MDD) is a highly prevalent and debilitating mental disorder, which is expected to be a leading contributor to global disease burden by 2030 [Reference Le, Wong, Lu, Vasudeva, Gill and Badulescu1–Reference Maj, Stein, Parker, Zimmerman, Fava and De Hert3]. Findings from extant literature indicate MDD is associated with reduced quality of life and increased economic burden [Reference Cui, Li, Wang, Wu, Liu and Yu4–Reference Thaipisuttikul, Ittasakul, Waleeprakhon, Wisajun and Jullagate6].

While monoaminergic antidepressants (e.g., selective serotonin reuptake inhibitors [SSRIs] and serotonin-norepinephrine reuptake inhibitors) are first-line pharmacotherapies for persons with MDD, a substantial proportion of patients fail to achieve a clinically meaningful response [Reference Le, Wong, Lu, Vasudeva, Gill and Badulescu1, Reference Saragoussi, Touya, Haro, Jönsson, Knapp and Botrel7, Reference Singh, Hazari, Mittal, Yadav, Kumar and Mishra8]. Persons with MDD and an inadequate response to two or more antidepressants are classified as having treatment-resistant depression (TRD) [Reference McIntyre, Alsuwaidan, Baune, Berk, Demyttenaere and Goldberg9].

Ketamine and esketamine have demonstrated rapid, robust and sustained antidepressant effects in TRD [Reference Calder, Kwan, Teopiz, Wong, Rosenblat and Mansur10–Reference Quintero, Bustos, Lechtig-Wassermann, Beltran and Zarate12]. Ketamine and esketamine’s antidepressant mechanism of action is posited to include N-methyl-D-aspartate (NMDA) receptor antagonism on GABAergic interneurons, resulting in glutamatergic disinhibition and increased AMPA receptor expression and activity [Reference Aleksandrova and Phillips13–Reference McIntyre and Jain16].

However, findings from extant literature suggest that NMDA receptor antagonism may not fully account for ketamine and esketamine’s antidepressant effects [Reference Antos, Żukow, Bursztynowicz and Jakubów17–Reference Zanos and Gould19]. Emerging evidence suggests potential involvement of the opioidergic system [Reference Adzic, Lukic, Mitic, Glavonic, Dragicevic and Ivkovic20, Reference Grasso, Tennyson, Airan and Di Ianni21]. Specifically at subanesthetic doses, ketamine and esketamine nonselectively interact with mu-opioid (MORs), delta-opioid (DORs), and kappa-opioid (KORs) receptors, suggesting that their antidepressant effects may involve opioid signaling pathways [Reference Niesters, Martini and Dahan22, Reference Williams, Heifets, Blasey, Sudheimer, Pannu and Pankow23]. Furthermore, preliminary evidence suggests that the pathophysiology of depression may involve dysregulation of endogenous opioid signaling (e.g., reduced endogenous MOR availability and KOR hyperactivation) [Reference Jawad, Alnefeesi, Lui, Ceban, Chen-Li and Teopiz24–Reference Nummenmaa, Karjalainen, Isojärvi, Kantonen, Tuisku and Kaasinen26].

Herein, the present systematic review aims to comprehensively and critically evaluate available literature on whether opioid signaling may contribute to ketamine- and/or esketamine-associated clinical symptom outcomes. This area of research holds critical implications for elucidating the mechanisms underlying ketamine and/or esketamine’s antidepressant efficacy, as well as informing safety guidelines for potential abuse liability.

Methods

Search strategy

This review followed the 2020 Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines [Reference Page, Moher, Bossuyt, Boutron, Hoffmann and Mulrow27]. The systematic search was conducted by retrieving articles from databases, including PubMed/MEDLINE, Cochrane Library, Embase, AMED, PsycINFO and Joanna Briggs Institute (JBI) EBP databases. The search string employed for each database included terms relevant to ketamine and esketamine, depression, opioid systems/mechanisms, and human and animal studies (Supplementary Table S1). The search occurred from inception to September 27, 2025. In addition, no search filters were applied to retrieve all potentially relevant studies.

Study selection and eligibility criteria

Covidence was used to screen studies [28]. Two independent reviewers (A.L. and H.X.) conducted title and abstract screening for relevant studies, followed by full-text screening. Only articles deemed relevant according to the eligibility criteria (Table 1) were included for data extraction and analysis. Any conflicts were resolved between the two independent reviewers. While Covidence removed duplicate studies, a few additional duplicates were manually removed.

Table 1.

Eligibility criteria

Studies were eligible for inclusion if they reported primary research examining the potential role of opioid systems or mechanisms in mediating the antidepressant efficacy of ketamine or esketamine. Human participants must have been diagnosed with a depressive disorder (i.e., MDD, bipolar depression [BD], TRD, or treatment-resistant BD). For animal studies, a validated depression model must have been employed before the administration of ketamine or esketamine.

Data extraction

Data extraction was conducted by two independent reviewers (A.L. and H.X.). Extracted study characteristics for clinical/human studies were established a priori and included: (1) the first author and year of publication, (2) study design, (3) primary diagnosis, (4) total sample size (included in relevant analyses), (5) control, (6) dosage with sample size, (7) dosing frequency, (8) measure(s) (for depression), and (9) antidepressant efficacy outcomes (Table 2). Similar characteristics were extracted for preclinical/animal studies; the type of model, behavioral outcomes, and brain slice findings were extracted (Table 3).

Table 2.

Characteristics of clinical studies investigating the potential mediating effect of the opioid system on antidepressant efficacy of ketamine or esketamine in persons with depressive disorders (n = 12)

Abbreviations: ACC, anterior cingulate cortex; BDI-II, Beck Depression Inventory-Second Edition; BUP, buprenorphine; C-SSRS, Columbia Suicide Severity Rating Scale; ELISA, enzyme-linked immunosorbent assay; Glx, combined measure of glutamate and glutamine; GWAS, genome-wide association studies; HADS, Hospital Anxiety and Depression Scale; HAM-D, Hamilton Depression Rating Scale; HC, healthy controls; HDRS, Hamilton Depression Rating Scale; H-fMRS, proton functional magnetic resonance spectroscopy; IM, intramuscularly; IN, intranasal; IV, intravenous; KOR, kappa opioid receptor; M, mean; M3VAS, Maudsley 3-item Visual Analogue Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; MD, mean difference; MDD, major depressive disorder; MDZ, midazolam; MOR, mu opioid receptor; MTD, methadone; NR, not reported; NS, not significant; NTX, naltrexone; OR, odds ratio; POMS, Profile of Mood States; QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report; RCT, randomized controlled trial; SD, standard deviation; SHAPS, Snaith–Hamilton Pleasure Scale; SNP, single nucleotide polymorphism; SNR, signal-to-noise ratio; SSI, Beck Scale for Suicidal Ideation; TEPS, Temporal Experience of Pleasure Scale; TEPS-A, TEPS anticipatory subscale; TEPS-C, TEPS consummatory subscale; tNAA, N-acetylaspartate + N-acetylaspartylglutamate; TRD, treatment resistant depression.

Table 3.

Characteristics of preclinical studies investigating the potential mediating effect of the opioid system on behavioral outcomes of ketamine in depressed animal models (n = 4)

Abbreviations: ACSF, artificial cerebrospinal fluid; cLH, congenital learned helplessness; CORT, corticosterone; CSDS, chronic social defeat stress; CTAP, D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2; CUS, chronic unpredictable stress; FAT, feed approach test; FST, forced swim test; IP, intraperitoneal; IPA, Ingenuity Pathway Analysis; LHb, lateral habenula; LPS, lipopolysaccharide-induced inflammation; mFST, modified forced swim test; NTT, novel tank test; NTX, naltrexone; PRT, progressive ratio task; SI, social interaction test; SPT, sucrose preference test; SC, subcutaneous; TRT, threat response test; TST, tail suspension test; WT, wild type.

Quality assessments

Using the National Institutes of Health tools, independent reviewers (A.L. and H.X.) appraised the included clinical/human studies. In particular, this review utilized the Quality Assessment of Controlled Intervention Studies, the Quality Assessment of Observational Cohort and Cross-Sectional Studies, and the Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group [Reference Ma, Wang, Yang, Huang, Weng and Zeng29, 30]. In addition, the JBI Critical Appraisal Tool for Case Reports was used [Reference Ma, Wang, Yang, Huang, Weng and Zeng29, 31]. For preclinical/animal studies, the SYRCLE’s Risk of Bias tool was utilized [Reference Hooijmans, Rovers, de Vries, Leenaars, Ritskes-Hoitinga and Langendam32]. Any disagreements in assessments were resolved through discussion.

Results

Search results

The search strategy yielded 784 studies after removing duplicates (n = 161). Using the eligibility criteria for screening (Table 1), 36 studies remained after title and abstract screening, and 16 studies were included in this review after full-text screening (n = 4 preclinical studies; n = 12 clinical studies). Reasons for excluding studies in full-text screening included the wrong animal model (n = 11), no full-text (n = 8), and the wrong intervention (n = 1). Other details can be found in the PRISMA flow diagram (Figure 1).

Figure 1.

PRISMA flow diagram of literature search.

Source: Page MJ, et al. BMJ 2021;372:n71. doi: 10.1136/bmj.n71 [28].

Methodological quality assessment

Preclinical/animal studies were evaluated as a moderate risk of bias [Reference Klein, Chandra, Sheriff and Malinow33–Reference Reddy, Babu, Das, Bhattacharya, Murthy and Kumar36]. These evaluations were largely due to the lack of reporting of several study design details. Among clinical studies, controlled intervention studies had a low risk of bias [Reference Williams, Heifets, Blasey, Sudheimer, Pannu and Pankow23, Reference Williams, Heifets, Bentzley, Blasey, Sudheimer and Hawkins37–Reference Saad, Hibar, Fedgchin, Popova, Furey and Singh44]. Similarly, Marton et al. [Reference Marton, Barnes, Wallace and Woolley45] was an observational cohort study, and Hosanagar et al. [Reference Hosanagar, Schmale and LeBlanc46] was a case report; they were deemed moderate and low risk of bias, respectively. In contrast, Yoon et al. [Reference Yoon, Petrakis and Krystal47] was a pre-post study with no control group, and the only study assessed as high in risk of bias. All assessments can be found in the Supplementary Materials (Supplementary Tables S2–S6).

Overview of preclinical and clinical study characteristics

There were four preclinical studies that examined ketamine with animal models of depression; none of the studies examined esketamine. A subanesthetic dose of ketamine was administered either through intraperitoneal injection (i.e., 10–30 mg/kg) [Reference Klein, Chandra, Sheriff and Malinow33–Reference Zhang and Hashimoto35], artificial cerebrospinal fluid perfusate (i.e., 10 μM) [Reference Klein, Chandra, Sheriff and Malinow33], or immersion in a water tank (i.e., 20 mg/L) [Reference Reddy, Babu, Das, Bhattacharya, Murthy and Kumar36].

Across all 12 clinical studies (n = 9 controlled intervention, n = 1 observational cohort, n = 1 pre-post with no control group, and n = 1 case report), a total of 706 participants (n = 264 MDD and n = 526 TRD) were included. Eleven studies investigated a subanesthetic dose of intravenous (IV) ketamine (i.e., 0.2 or 0.5 mg/kg) [Reference Williams, Heifets, Blasey, Sudheimer, Pannu and Pankow23, Reference Williams, Heifets, Bentzley, Blasey, Sudheimer and Hawkins37–Reference Grunebaum, Galfalvy, Liu, Huang, Marcott and Burke43, Reference Marton, Barnes, Wallace and Woolley45, Reference Hosanagar, Schmale and LeBlanc46, Reference Yoon, Petrakis and Krystal47]. Intranasal esketamine (i.e., 84 mg) was investigated in only one study [Reference Saad, Hibar, Fedgchin, Popova, Furey and Singh44].

Preclinical/animal studies

Effect of opioid antagonists on ketamine

Naltrexone (i.e., NTX; a nonselective opioid antagonist) attenuated ketamine’s effects in congenitally learned helplessness rats (i.e., rat model of depression) [Reference Klein, Chandra, Sheriff and Malinow33]. Significantly greater immobility time in the forced swimming test (FST) was observed in depressed rats receiving NTX combined with ketamine compared to ketamine-placebo (p < 0.05) [Reference Klein, Chandra, Sheriff and Malinow33]. In line with the foregoing trend, ketamine significantly increased effort exerted to obtain rewards in the progressive ratio task, indexing improvements in anhedonia symptom severity; however, this effect was not observed in the NTX-ketamine group (F = 5.79, p < 0.05) [Reference Klein, Chandra, Sheriff and Malinow33]. Furthermore, NTX also inhibited ketamine-induced reductions in lateral habenula (LHb) activity (i.e., LHb hyperactivity is associated with depression) (p < 0.05) [Reference Klein, Chandra, Sheriff and Malinow33].

Separately, NTX did not attenuate ketamine’s antidepressant effects in stress-induced mice, wherein a nonsignificant between-group difference in immobility time was observed [Reference Pomrenze, Vaillancourt, Llorach, Rijsketic, Casey and Gregory34]. Comparably, in other stress-induced models, ketamine produced antidepressant-like effects across the FST (F = 6.672, p < 0.001; F = 3.627, p = 0.014), tail suspension test (TST) (F = 9.473, p < 0.001), and sucrose preference test (F = 5.146, p = 0.002), with no observed attenuation by NTX coadministration [Reference Zhang and Hashimoto35].

Beyond NTX, D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (opioid antagonist) also inhibited ketamine-induced reductions in LHb activity (p < 0.05) [Reference Klein, Chandra, Sheriff and Malinow33].

Regulation of opioid signaling by ketamine

In a chronic unpredictable stress model of zebrafish, ketamine elicited improved performance in the social interaction test, feed approach test, novel tank test and TST [Reference Reddy, Babu, Das, Bhattacharya, Murthy and Kumar36]. These behavioral effects were accompanied by normalization of dysregulated opioid signaling. Ketamine restored the expression or function of opioid-related proteins, including RICTOR, PER2 and CABP1, to baseline levels [Reference Reddy, Babu, Das, Bhattacharya, Murthy and Kumar36].

Clinical/human studies

Effect of NTX on ketamine

In a crossover randomized controlled trial (RCT), NTX significantly attenuated both the overall antidepressant and anti-suicidal effects of ketamine in patients with TRD (n = 12) [Reference Williams, Heifets, Blasey, Sudheimer, Pannu and Pankow23, Reference Williams, Heifets, Bentzley, Blasey, Sudheimer and Hawkins37]. Among ketamine responders (n = 7), reductions in Hamilton Depression Rating Scale (HDRS) total scores were significantly greater when administered placebo-ketamine compared to NTX-ketamine (HDRS 17-item: F = 43.7, p < 0.001; HDRS 6-item: F = 29.8, p = 0.002) [Reference Williams, Heifets, Blasey, Sudheimer, Pannu and Pankow23]. No significant difference was observed on days 5, 7 and 14 post-treatment [Reference Williams, Heifets, Blasey, Sudheimer, Pannu and Pankow23]. In addition, five out of seven responders achieved remission (a score of ≤7 on the HDRS) when administered placebo-ketamine, whereas none met the criteria when administered NTX-ketamine [Reference Williams, Heifets, Blasey, Sudheimer, Pannu and Pankow23]. The attenuation effect of NTX was consistent in the Montgomery-Åsberg Depression Rating Scale (MADRS), Beck Depression Inventory Second Edition (BDI-II), and Columbia Suicide Severity Rating Scale (C-SSRS) scores, and in all participants [Reference Williams, Heifets, Blasey, Sudheimer, Pannu and Pankow23, Reference Williams, Heifets, Bentzley, Blasey, Sudheimer and Hawkins37]. Notably, among responders, reductions differed significantly between groups for HDRS suicidal ideation (SI) score (all p ≤ 0.02), MADRS SI score (all p ≤ 0.002), and C-SSRS (all p ≤ 0.006) [Reference Williams, Heifets, Bentzley, Blasey, Sudheimer and Hawkins37].

Conversely, in an observational cohort study of TRD patients, a patient (n = 1) received NTX-ketamine and reported BDI-II scores comparable to patients (n = 34) receiving ketamine alongside buprenorphine (i.e., partial MOR agonist), methadone (i.e., full MOR agonist), or no MOR agent [Reference Marton, Barnes, Wallace and Woolley45]. Consistent with the foregoing findings, an open-label study of patients with MDD and alcohol use disorder (AUD) (n = 5) received NTX-ketamine and all achieved clinical response by the fourth infusion (50% reduction in MADRS scores), demonstrating MADRS reductions ranging from 57 to 92% after 4 weeks of treatment [Reference Yoon, Petrakis and Krystal47]. Similarly, in an RCT study, patients with MDD and AUD (n = 58) received NTX-ketamine, saline-ketamine or midazolam-ketamine and showed no significant differences in clinical response (p = 0.63) [Reference Yoon, Pittman, Ralevski, Petrakis and Krystal38]. MADRS scores were similar across conditions 60 min before (F 10,214 = 0.77, p = 0.66) and 240 min after infusion (F 10,213 = 1.79, p = 0.06) [Reference Yoon, Pittman, Ralevski, Petrakis and Krystal38].

In contrast, a crossover RCT of patients with MDD (n = 26) compared NTX-ketamine with placebo-ketamine and reported mixed evidence for opioid-mediated antidepressant effects [Reference Jelen, Lythgoe, Stone, Young and Mehta39]. In all participants, reductions in MADRS scores significantly differed between conditions on day 1 of post-infusion (F 1,74 = 5.39, p = 0.023) [Reference Jelen, Lythgoe, Stone, Young and Mehta39]. However, the foregoing finding was not replicated on days 1, 3 and 7 in self-report measures, including the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR), Maudsley 3-item Visual Analogue Scale, Snaith Hamilton Pleasure Scale (SHAPS), and Temporal Experience of Pleasure Scale anticipatory anhedonia subscale (TEPS-A) and consummatory anhedonia subscale (TEPS-C) (all p > 0.05) [Reference Jelen, Lythgoe, Stone, Young and Mehta39]. Among ketamine responders, the attenuation effect of NTX was more robust (MADRS: F 1,38 = 15.33, p < 0.001; QIDS-SR: F 1,38 = 10.51, p = 0.003) [Reference Jelen, Lythgoe, Stone, Young and Mehta39]. Response and remission rates were generally comparable between conditions, except for a lower MADRS remission in the NTX-ketamine condition on day 1 of post-infusion (p = 0.034) [Reference Jelen, Lythgoe, Stone, Young and Mehta39]. In a neuroimaging subsample (n = 24) using proton functional magnetic resonance spectroscopy, Glx/tNAA (glutamate + glutamine/N-acetylaspartate + N-acetylaspartylglutamate) ratios in the anterior cingulate cortex (ACC) increased significantly during ketamine infusion, but this increase was attenuated in the NTX-ketamine condition compared with placebo-ketamine (F 1,253 = 4.83, p = 0.029) [Reference Jelen, Lythgoe, Stone, Young and Mehta39].

Effect of opioid use on ketamine

In a case report of a patient with TRD and active SI, Hosanagar et al. [Reference Hosanagar, Schmale and LeBlanc46] reported a robust decrease in MADRS total and SI score after the first and second infusion of ketamine-buprenorphine. Mood improvements were sustained, with no report of SI 4 weeks post-treatment [Reference Hosanagar, Schmale and LeBlanc46]. Similarly, Marton et al. [Reference Marton, Barnes, Wallace and Woolley45] did not observe a significant difference in reductions in BDI-II scores between TRD patients administered ketamine with oral buprenorphine or methadone (n = 7) compared to ketamine only (n = 27) (p = 0.11).

In a separate double-blind RCT study of patients with MDD (n = 40), baseline opioid use status did not significantly predict post-treatment MADRS scores (t = −0.40, p = 0.686), % change in MADRS scores (t = 0.25, p = 0.806), post-treatment Hospital Anxiety and Depression Scale (HADS) scores (t = 1.15, p = 0.251), and % change in HADS scores (t = 0.85, p = 0.397) [Reference Lii, Flohr, Okada, Cianfichi, Hack and Schatzberg40]. In addition, postoperative opioid use status did not significantly predict post-treatment MADRS (t = −0.23, p = 0.819) and HADS scores (t = 0.24, p = 0.814) [Reference Lii, Flohr, Okada, Cianfichi, Hack and Schatzberg40].

Molecular biomarkers: KOR and dynorphin plasma levels

In a double-blind crossover RCT of MDD patients (n = 64), no significant drug × time × plasma levels of soluble KORs interaction was found for MADRS (F = 0.36, p = 0.70), SHAPS (F = 0.02, p = 0.98), TEPS total score (F = 0.60, p = 0.55), and TEPS-A (F = 0.23, p = 0.79) or TEPS-C (F = 1.27, p = 0.29) [Reference Quintanilla, Medeiros, Greenstein, Yuan, Johnston and Park41]. In line with the foregoing trend, a nonsignificant interaction was observed for plasma levels of dynorphins in MADRS (F = 1.19, p = 0.31), SHAPS (F = 0.48, p = 0.62), TEPS total score (F = 1.10, p = 0.34), and TEPS-A (F = 1.28, p = 0.29) or TEPS-C (F = 1.08, p = 0.35) [Reference Quintanilla, Medeiros, Greenstein, Yuan, Johnston and Park41].

Ketamine and opioid gene variants

In a double-blind RCT of TRD patients (n = 65), Kao et al. [Reference Kao, Tsai, Su, Li, Lin and Hong42] observed a significant association between the OPRD1 gene and reductions in HDRS (p ≤ 0.049) and MADRS scores (p = 0.047) post-treatment of ketamine. In addition, the OPRM1 gene was associated with a clinical response (50% reduction) in HDRS (p = 0.033) and MADRS scores (p = 0.026) [Reference Kao, Tsai, Su, Li, Lin and Hong42]. Notably, the OPRM1 variant rs2473546 was associated with clinical response in HDRS scores (odds ratio [OR] = 4.07, p = 0.0069); the rs9479827 variant was also associated with clinical response in MADRS scores (OR = 6.04, p = 0.0083) [Reference Kao, Tsai, Su, Li, Lin and Hong42].

However, in a double-blind RCT of MDD patients with active SI (n = 71), Grunebaum et al. [Reference Grunebaum, Galfalvy, Liu, Huang, Marcott and Burke43] observed no significant interaction between the OPRM1 A118G polymorphism and ketamine response, particularly in HDRS-17 (t = 0.78, p = 0.439), HDRS-24 (t = 0.55, p = 0.582), Beck Scale for Suicidal Ideation (t = 0.59, p = 0.554), and Profile of Mood States scores (t = 0.61, p = 0.544).

Esketamine and opioid gene variants

In a double-blind RCT of TRD patients (n = 406), Saad et al. [Reference Saad, Hibar, Fedgchin, Popova, Furey and Singh44] observed that the OPRM1 variant rs1799971 was not significantly associated with reductions in MADRS scores on days 2 and 28 post-treatment of esketamine combined with an antidepressant (p = 0.69, R2 partial = < 0.5%; p = 0.34, R2 partial = < 0.5%). In accordance, no significant association with esketamine response was observed for the OPRM1 variant rs34427887 [Reference Saad, Hibar, Fedgchin, Popova, Furey and Singh44].

Discussion

To our knowledge, this is the first systematic review to comprehensively evaluate the role of opioid signaling in the mechanisms of action of ketamine’s and esketamine’s antidepressant efficacy. Studies reported that opioid antagonists (e.g., NTX) may attenuate ketamine’s antidepressant efficacy, particularly in small, randomized crossover trials. In contrast, larger randomized trials generally found no consistent moderation by opioid-related gene expression (i.e., OPRM1 and OPRD1) or plasma biomarkers (KOR and dynorphin). Separately, opioid use (e.g., buprenorphine and methadone) did not significantly alter response to ketamine. Although definitive conclusions cannot be drawn, trends across preclinical and clinical evidence support a partial mediating effect of the opioid system on ketamine’s and esketamine’s antidepressant effects in persons with TRD.

Separately, all but one study involving persons with MDD did not observe any support for a mediation effect. The foregoing distinction may be attributed to neuropathophysiological differences between TRD and MDD populations, potentially accounting for differential treatment response [Reference McIntyre, Alsuwaidan, Baune, Berk, Demyttenaere and Goldberg9, Reference Gutierrez, Swainson, Ravindran, Lam, Giacobbe and Karthikeyan48–Reference Zolghadriha, Anjomshoaa, Jamshidi and Taherkhani54]. In particular, TRD is associated with lower ACC GABA levels and smaller hippocampal volumes than MDD, indicating greater GABAergic dysfunction [Reference Abdallah, Jackowski, Sato, Mao, Kang and Cheema55]. More pronounced GABAergic deficits in TRD may render ketamine’s antidepressant effects increasingly dependent on opioid-mediated mechanisms, thereby causing NTX antagonism to be consistently disruptive. In contrast, in MDD, relatively preserved GABAergic function may subserve partial antidepressant efficacy, notwithstanding opioid receptor antagonism.

Differences in the pharmacological profiles of ketamine and esketamine, as well as the hypothesized distinct roles of MOR, DOR and KOR receptors in depression pathophysiology and antidepressant response, may also contribute to the observed variability in our findings (Supplementary Table S7) [Reference Niesters, Martini and Dahan22, Reference Williams, Heifets, Blasey, Sudheimer, Pannu and Pankow23, Reference Jelen, Stone, Young and Mehta25]. In addition, extant literature notes that subanesthetic ketamine and esketamine doses exhibit low binding affinity for opioid receptors, which may limit receptor engagement and the detection of opioid-mediated effects [Reference Bonaventura, Lam, Carlton, Boehm, Gomez and Solís56–Reference Fricker, Osman, Gupta, Gomes and Devi60]. In particular, recent mechanistic studies suggest that ketamine and its metabolites act as positive allosteric modulators of MORs at standard antidepressant doses, enhancing opioid signaling rather than directly activating the receptor [Reference Fricker, Osman, Gupta, Gomes and Devi60]. The foregoing framework may reconcile our mixed clinical findings by positing that the antidepressant effects depend on individual differences in receptor availability or opioid system responsiveness, rather than direct MOR activation [Reference Fricker, Osman, Gupta, Gomes and Devi60].

Clinical implications

Our inconclusive findings warrant further investigation, with a specific focus in clarifying ketamine’s and esketamine’s antidepressant mechanisms and informing the development of novel therapeutics. However, our findings highlight several considerations. The lack of attenuation by opioid receptor antagonists suggests that receptor activation may not be essential for antidepressant response. Notwithstanding, the observed consistent attenuation in other studies involving TRD and the aforementioned factors that may underlie variability in our results, more likely suggest that the opioid system may function as a context-dependent modulator rather than a uniform mediator. The foregoing distinction underscores the need for stratified research designs that differentiate between MDD and TRD and account for individual variability in opioid receptor availability and expression, prior opioid exposure, and genetic polymorphisms.

In addition, at subanesthetic doses of IV ketamine, there is a concern for potential abuse liability [Reference Andrade61–Reference Trujillo and Iñiguez64]. A scoping review by Le et al. [Reference Andrade61] included four clinical studies and reported that patients with TRD showed no compelling evidence of dependence or diversion after a single or repeated ketamine administration in a professionally controlled setting. Similarly, results from pharmacovigilance and other inquiries have not provided evidence of drug abuse, misuse, diversion or gateway activity with ketamine or esketamine when administered under clinical supervision [Reference Kwan, Lakhani, Rosenblat, Mansur, Rhee and Teopiz65–Reference Kwan, Rosenblat, Mansur, Teopiz and McIntyre67]. The Food and Drug Administration (FDA)―mandated Risk Evaluation and Mitigation Strategy for esketamine has also likely contributed to the reduced risk profile observed [Reference Roncero, Merizalde-Torres, Szerman, Torrens, Vega and Andres-Olivera68]. However, clinical evidence remains limited, warranting further investigation [Reference Levinstein, Carlton, Di Ianni, Ventriglia, Rizzo and Gomez59, Reference Le, Cordero, Jawad, Swainson, Di Vincenzo and Jaberi62].

Limitations and future directions

Our review was limited to studies that investigated ketamine and esketamine in persons with depressive disorders and animal models of depression. Thus, we excluded studies on arketamine or ketamine metabolites. We also excluded preclinical studies during full-text review that used nondepressed animal models, most of which reported opioid-mediated mechanisms or irrelevant outcomes [Reference Bonaventura, Lam, Carlton, Boehm, Gomez and Solís56, Reference Levinstein, Carlton, Di Ianni, Ventriglia, Rizzo and Gomez59, Reference Langreck, Chen, Luna, Nelson, Turi and Hill69–Reference Di Ianni, Ewbank, Levinstein, Azadian, Budinich and Michaelides77]. Therefore, our results cannot be generalized to other human populations, animal models or glutamatergic modulators. Studies varied considerably, such as in study designs, sample sizes, routes of administration, dosage, dosing schedule, and outcome measures, limiting direct comparisons (Supplementary Tables S6–S10). Although our review included a comparable number of MDD and TRD studies, the sample was skewed toward TRD due to one large esketamine trial. However, findings remained inconclusive as it was the only esketamine study. The inclusion of only one esketamine study also limited opportunities for direct comparison with ketamine.

Further research should adopt rigorously controlled, stratified and dose-escalation RCT designs using opioid receptor-selective probes to more precisely delineate the role of the opioid system. It is also recommended that further mechanistic research investigate esketamine’s opioid interactions because of its FDA approval for depression and more widespread clinical use compared to ketamine [Reference Aguilar, Beauregard, Conroy, Khatiwoda, Horsford and Nichols78, Reference Vekhova, Namiot, Jonsson and Schiöth79].

Supplementary material

The supplementary material for this article can be found at http://doi.org/10.1192/j.eurpsy.2026.10157.

Data availability statement

This systematic review did not generate any new data. All extracted and analyzed data are provided in the Supplementary Materials and presented within the tables and figures of this article. Data from the original studies can be accessed through their respective publications or repositories.

Author contributions

Conceptualization: AL and RSM. Data curation: AL. Investigation: AL and HX. Methodology: AL. Project administration: AL. Resources: AL. Supervision: GHL and RSM. Validation: AL and HX. Visualization: AL. Writing – original draft preparation: AL. Writing – review and editing: All authors. All authors agree to be accountable for all aspects of the work. All authors have read and agreed to the submitted version of the manuscript.

Financial support

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interests

Dr. Roger S. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Bristol Myers Squibb (BMS) Teva, Adhere Tech, GH Research, Autobahn Theapeutics and Atai Life Sciences. Dr. Taeho Greg Rhee was supported in part by the National Institute on Aging (#R21AG070666, R21AG078972, and R01AG088647), National Institute of Mental Health (#R01MH131528), National Institute on Drug Abuse (#R21DA057540), and Health Resources and Services Administration (#R42MC53154–01-00). Dr. Rhee serves as a review committee member for the National Institutes of Health (NIH), Patient-Centered Outcomes Research Institute (PCORI), and Substance Abuse and Mental Health Services Administration (SAMHSA), and has received honoraria payments from NIH, PCORI, and SAMHSA. Dr. Rhee has also served as a stakeholder/consultant for PCORI and received consulting fees from PCORI. Dr. Rhee serves as an advisory committee member for the International Alliance of Mental Health Research Funders (IAMHRF). Dr. Guillen-Burgos has received research grant support from the Ministry of Science, Technology, and Innovation (Minciencias) in Colombia, UKRI in the United Kingdom; and speaker fees from Abbott, GSK, Roche, Pfizer, and Synergy R&D. All other authors declare no competing interests.

References

Le, GH, Wong, S, Lu, A, Vasudeva, S, Gill, H, Badulescu, S, et al. Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and Vortioxetine in major depressive disorder: a systematic review. J Affect Disord. 2024;368:798–819. doi:10.1016/j.jad.2024.09.081.Google Scholar
Liu, J, Liu, Y, Ma, W, Tong, Y, Zheng, J. Temporal and spatial trend analysis of all-cause depression burden based on global burden of disease (GBD) 2019 study. Sci Rep. 2024;14(1): doi:10.1038/s41598-024-62381-9.Google Scholar
Maj, M, Stein, DJ, Parker, G, Zimmerman, M, Fava, GA, De Hert, M, et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020;19(3):269–93. doi:10.1002/wps.20771.Google Scholar
Cui, L, Li, S, Wang, S, Wu, X, Liu, Y, Yu, W, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther. 2024;9(1): doi:10.1038/s41392-024-01738-y.Google Scholar
Greenberg, PE, Fournier, A-A, Sisitsky, T, Simes, M, Berman, R, Koenigsberg, SH, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). PharmacoEconomics. 2021;39(6):653–65. doi:10.1007/s40273-021-01019-4.Google Scholar
Thaipisuttikul, P, Ittasakul, P, Waleeprakhon, P, Wisajun, P, Jullagate, S. Psychiatric comorbidities in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014;2097 doi:10.2147/ndt.s72026.Google Scholar
Saragoussi, D, Touya, M, Haro, JM, Jönsson, B, Knapp, M, Botrel, B, et al. Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the perform study. Neuropsychiatr Dis Treat. 2017;13:2151–65. doi:10.2147/ndt.s136343.Google Scholar
Singh, N, Hazari, PP, Mittal, P, Yadav, SK, Kumar, N, Mishra, G, et al. Role of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and psychedelics in the treatment of major depressive disorder: a perspective on mechanistic insight and current status. Eur J Pharmacol. 2025;177737. doi:10.1016/j.ejphar.2025.177737.Google Scholar
McIntyre, RS, Alsuwaidan, M, Baune, BT, Berk, M, Demyttenaere, K, Goldberg, JF, et al. Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394–412. doi:10.1002/wps.21120.Google Scholar
Calder, CN, Kwan, ATH, Teopiz, KM, Wong, S, Rosenblat, JD, Mansur, RB, et al. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: a systematic review and meta-analysis. J Affect Disord. 2024;356:753–62. doi:10.1016/j.jad.2024.04.039.Google Scholar
McIntyre, RS, Rosenblat, JD, Nemeroff, CB, Sanacora, G, Murrough, JW, Berk, M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–99. doi:10.1176/appi.ajp.2020.20081251.Google Scholar
Quintero, JM, Bustos, RH, Lechtig-Wassermann, S, Beltran, S, Zarate, CA. Ketamine in clinical practice: transitioning from anesthetic agent to psychiatric therapeutic. CNS Spectr. 2025;1–42. doi:10.1017/s1092852925100333.Google Scholar
Aleksandrova, LR, Phillips, AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci. 2021;42(11):929–42. doi:10.1016/j.tips.2021.08.003.Google Scholar
Aleksandrova, LR, Phillips, AG, Wang, YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci. 2017;42(4):222–9. doi:10.1503/jpn.160175.Google Scholar
Gerhard, DM, Pothula, S, Liu, R-J, Wu, M, Li, X-Y, Girgenti, MJ, et al. GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions. J Clin Invest. 2020;130(3):1336–49. doi:10.1172/jci130808.Google Scholar
McIntyre, RS, Jain, R. Glutamatergic modulators for major depression from theory to clinical use. CNS Drugs. 2024;38(11):869–90. doi:10.1007/s40263-024-01114-y.Google Scholar
Antos, Z, Żukow, X, Bursztynowicz, L, Jakubów, P. Beyond NMDA receptors: a narrative review of ketamine’s rapid and multifaceted mechanisms in depression treatment. Int J Mol Sci. 2024;25(24):13658. doi:10.3390/ijms252413658.Google Scholar
Krystal, JH, Kavalali, ET, Monteggia, LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. 2023;49(1):41–50. doi:10.1038/s41386-023-01629-w.Google Scholar
Zanos, P, Gould, TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801–11. doi:10.1038/mp.2017.255.Google Scholar
Adzic, M, Lukic, I, Mitic, M, Glavonic, E, Dragicevic, N, Ivkovic, S. Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine. Life Sci. 2023;326:121803 doi:10.1016/j.lfs.2023.121803.Google Scholar
Grasso, V, Tennyson, J, Airan, RD, Di Ianni, T. Ketamine-induced static and dynamic functional connectivity changes are modulated by opioid receptors and biological sex in rats. Neuropsychopharmacology. 2025; doi:10.1038/s41386-025-02108-0.Google Scholar
Niesters, M, Martini, C, Dahan, A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77(2):357–67. doi:10.1111/bcp.12094.Google Scholar
Williams, NR, Heifets, BD, Blasey, C, Sudheimer, K, Pannu, J, Pankow, H, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175(12):1205–15. doi:10.1176/appi.ajp.2018.18020138.Google Scholar
Jawad, MY, Alnefeesi, Y, Lui, LMW, Ceban, F, Chen-Li, DCJ, Teopiz, K, et al. Olanzapine and samidorphan combination treatment: a systematic review. J Affect Disord. 2022;301:99–106. doi:10.1016/j.jad.2022.01.004.Google Scholar
Jelen, LA, Stone, JM, Young, AH, Mehta, MA. The opioid system in depression. Neurosci Biobehav Rev. 2022;140:104800 doi:10.1016/j.neubiorev.2022.104800.Google Scholar
Nummenmaa, L, Karjalainen, T, Isojärvi, J, Kantonen, T, Tuisku, J, Kaasinen, V, et al. Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety. Neuropsychopharmacology. 2020;45(11):1953–9. doi:10.1038/s41386-020-0725-9.Google Scholar
Page, MJ, Moher, D, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al. Prisma 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021; doi:10.1136/bmj.n160.Google Scholar
Covidence [Internet]. 2025 [cited 2025 May 26]. Available from: https://www.covidence.org/Google Scholar
Ma, L-L, Wang, Y-Y, Yang, Z-H, Huang, D, Weng, H, Zeng, X-T. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1): doi:10.1186/s40779-020-00238-8.Google Scholar
NIH. Study Quality Assessment Tools [Internet]. U.S. Department of Health and Human Services; 2021 [cited 2025 May 26]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-toolsGoogle Scholar
JBI. Critical Appraisal Tools [Internet]. 2020 [cited 2025 Jun 8]. Available from: https://jbi.global/critical-appraisal-toolsGoogle Scholar
Hooijmans, CR, Rovers, MM, de Vries, RB, Leenaars, M, Ritskes-Hoitinga, M, Langendam, MW. SYRCLE’S risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(1). doi:10.1186/1471-2288-14-43.Google Scholar
Klein, ME, Chandra, J, Sheriff, S, Malinow, R. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc Natl Acad Sci. 2020;117(5):2656–62. doi:10.1073/pnas.1916570117.Google Scholar
Pomrenze, MB, Vaillancourt, S, Llorach, P, Rijsketic, DR, Casey, AB, Gregory, N, et al. Ketamine evokes acute behavioral effects via μ-opioid receptor expressing neurons of the central amygdala. Biol Psychiatry. 2025; doi:10.1016/j.biopsych.2025.04.020.Google Scholar
Zhang, K, Hashimoto, K. Lack of opioid system in the antidepressant actions of ketamine. Biol Psychiatry. 2019;85(6). doi:10.1016/j.biopsych.2018.11.006.Google Scholar
Reddy, BR, Babu, NS, Das, T, Bhattacharya, D, Murthy, CL, Kumar, A, et al. Proteome profile of telencephalon associates attenuated neurogenesis with chronic stress induced mood disorder phenotypes in zebrafish model. Pharmacol Biochem Behav. 2021;204:173170. doi:10.1016/j.pbb.2021.173170.Google Scholar
Williams, NR, Heifets, BD, Bentzley, BS, Blasey, C, Sudheimer, KD, Hawkins, J, et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry. 2019;24(12):1779–86. doi:10.1038/s41380-019-0503-4.Google Scholar
Yoon, G, Pittman, B, Ralevski, E, Petrakis, IL, Krystal, JH. Antidepressant efficacy of ketamine plus naltrexone for major depression comorbid with alcohol use disorder: a randomized controlled trial. Int J Neuropsychopharmacol. 2025;28(8). doi:10.1093/ijnp/pyaf056.Google Scholar
Jelen, LA, Lythgoe, DJ, Stone, JM, Young, AH, Mehta, MA. Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study. Nat Med. 2025;31(9):2958–66. doi:10.1038/s41591-025-03800-w.Google Scholar
Lii, TR, Flohr, JR, Okada, RL, Cianfichi, LJ, Hack, LM, Schatzberg, AF, et al. Opioids diminish the placebo antidepressant response: observational post hoc findings from a randomized controlled ketamine trial. J Affect Disord. 2025;381:200–4. doi:10.1016/j.jad.2025.04.008.Google Scholar
Quintanilla, B, Medeiros, GC, Greenstein, D, Yuan, P, Johnston, JN, Park, LT, et al. Κ-opioid receptor plasma levels are associated with sex and diagnosis of major depressive disorder but not response to ketamine. J Clin Psychopharmacol. 2023;43(2):89–96. doi:10.1097/jcp.0000000000001663.Google Scholar
Kao, C-F, Tsai, S-J, Su, T-P, Li, C-T, Lin, W-C, Hong, C-J, et al. Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression. J Psychopharmacol. 2025. doi:10.1177/02698811251326939.Google Scholar
Grunebaum, MF, Galfalvy, HC, Liu, J, Huang, Y, Marcott, S, Burke, AK, et al. Opioid receptor μ-1 and ketamine effects in a suicidal depression trial. J Clin Psychopharmacol. 2020;40(4):420–2. doi:10.1097/jcp.0000000000001237.Google Scholar
Saad, Z, Hibar, D, Fedgchin, M, Popova, V, Furey, ML, Singh, JB, et al. Effects of mu-opiate receptor gene polymorphism RS1799971 (A118G) on the antidepressant and dissociation responses in Esketamine nasal spray clinical trials. Int J Neuropsychopharmacol. 2020;23(9):549–58. doi:10.1093/ijnp/pyaa030.Google Scholar
Marton, T, Barnes, DE, Wallace, A, Woolley, JD. Concurrent use of buprenorphine, methadone, or naltrexone does not inhibit ketamine’s antidepressant activity. Biol Psychiatry. 2019;85(12): doi:10.1016/j.biopsych.2019.02.008.Google Scholar
Hosanagar, A, Schmale, A, LeBlanc, A. Ketamine’s rapid antisuicidal effects are not attenuated by buprenorphine. J Affect Disord. 2021;282:252–4. doi:10.1016/j.jad.2020.12.120.Google Scholar
Yoon, G, Petrakis, IL, Krystal, JH. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry. 2019;76(3):337. doi:10.1001/jamapsychiatry.2018.3990.Google Scholar
Gutierrez, G, Swainson, J, Ravindran, N, Lam, RW, Giacobbe, P, Karthikeyan, G, et al. In esketamine and IV ketamine: results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression. Psychiatry Res. 2024;340:116125. doi:10.1016/j.psychres.2024.116125.Google Scholar
Hock, RS, Feeney, A, Iovieno, N, Murrough, JW, Mathew, SJ, Iosifescu, DV, et al. Rapidity of symptom improvement with intranasal esketamine for major depressive disorder. J Clin Psychiatry. 2022;84(1). doi:10.4088/jcp.21r14086.Google Scholar
Lundberg, J, Cars, T, Lööv, S-Å, Söderling, J, Sundström, J, Tiihonen, J, et al. Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study. JAMA Psychiatry. 2022;80(2):167. doi:10.1001/jamapsychiatry.2022.3860.Google Scholar
Miola, A, Meda, N, Perini, G, Sambataro, F. Structural and functional features of treatment‐resistant depression: a systematic review and exploratory coordinate‐based meta‐analysis of neuroimaging studies. Psychiatry Clin Neurosci. 2023;77(5):252–63. doi:10.1111/pcn.13530.Google Scholar
Pilon, D, Joshi, K, Sheehan, JJ, Zichlin, ML, Zuckerman, P, Lefebvre, P, et al. Burden of treatment-resistant depression in Medicare: a retrospective claims database analysis. PLoS One. 2019;14(10). doi:10.1371/journal.pone.0223255.Google Scholar
Runia, N, Yücel, DE, Lok, A, de Jong, K, Denys, DAJP, van Wingen, GA, et al. The neurobiology of treatment-resistant depression: a systematic review of neuroimaging studies. Neurosci Biobehav Rev. 2022;132:433–48. doi:10.1016/j.neubiorev.2021.12.008.Google Scholar
Zolghadriha, A, Anjomshoaa, A, Jamshidi, MR, Taherkhani, F. Rapid and sustained antidepressant effects of intravenous ketamine in treatment-resistant major depressive disorder and suicidal ideation: a randomized clinical trial. BMC Psychiatry. 2024;24(1). doi:10.1186/s12888-024-05716-0.Google Scholar
Abdallah, CG, Jackowski, A, Sato, JR, Mao, X, Kang, G, Cheema, R, et al. Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur Neuropsychopharmacol. 2015;25(8):1082–90. doi:10.1016/j.euroneuro.2015.04.025.Google Scholar
Bonaventura, J, Lam, S, Carlton, M, Boehm, MA, Gomez, JL, Solís, O, et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry. 2021;26(11):6704–22. doi:10.1038/s41380-021-01093-2.Google Scholar
Gupta, A, Devi, LA, Gomes, I. Potentiation of μ‐opioid receptor‐mediated signaling by ketamine. J Neurochem. 2011;119(2):294–302. doi:10.1111/j.1471-4159.2011.07361.x.Google Scholar
Hirota, K, Lambert, DG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth. 1996;77(4):441–4. doi:10.1093/bja/77.4.441.Google Scholar
Levinstein, MR, Carlton, ML, Di Ianni, T, Ventriglia, EN, Rizzo, A, Gomez, JL, et al. Mu opioid receptor activation mediates (s)-ketamine reinforcement in rats: implications for abuse liability. Biol Psychiatry. 2023;93(12):1118–26. doi:10.1016/j.biopsych.2022.12.019.Google Scholar
Fricker, LD, Osman, A, Gupta, A, Gomes, I, Devi, LA. Antidepressants and the endogenous opioid system. Biochem Pharmacol. 2025;242:117392 doi:10.1016/j.bcp.2025.117392.Google Scholar
Andrade, C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78(7). doi:10.4088/jcp.17f11738.Google Scholar
Le, TT, Cordero, IP, Jawad, MY, Swainson, J, Di Vincenzo, JD, Jaberi, S, et al. The abuse liability of ketamine: a scoping review of preclinical and clinical studies. J Psychiatr Res. 2022;151:476–96. doi:10.1016/j.jpsychires.2022.04.035.Google Scholar
Strong, CE, Kabbaj, M. On the safety of repeated ketamine infusions for the treatment of depression: effects of sex and developmental periods. Neurobiol Stress. 2018;9:166–75. doi:10.1016/j.ynstr.2018.09.001.Google Scholar
Trujillo, KA, Iñiguez, SD. Ketamine beyond anesthesia: antidepressant effects and abuse potential. Behav Brain Res. 2020;394:112841. doi:10.1016/j.bbr.2020.112841.Google Scholar
Kwan, ATH, Lakhani, M, Rosenblat, JD, Mansur, RB, Rhee, TG, Teopiz, KM, et al. A global population-based study on the association between ketamine and Esketamine with suicidality using WHO VIGIBASE. J Clin Psychiatry. 2025;86(3). doi:10.4088/jcp.24m15534.Google Scholar
Kwan, ATH, Rosenblat, JD, Mansur, RB, Rhee, TG, Teopiz, K, Le, GH, et al. A replication study using the World Health Organization Pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and Esketamine and alcohol and substance misuse exists. J Affect Disord. 2024;363:589–94. doi:10.1016/j.jad.2024.07.128.Google Scholar
Kwan, ATH, Rosenblat, JD, Mansur, RB, Teopiz, KM, McIntyre, RS. The association between ketamine and Esketamine with alcohol and substance misuse: reports to the Food and Drug Administration adverse event reporting system (FAERS). J Affect Disord. 2024;360:421–6. doi:10.1016/j.jad.2024.05.116.Google Scholar
Roncero, C, Merizalde-Torres, M, Szerman, N, Torrens, M, Vega, P, Andres-Olivera, P, et al. Is there a risk of esketamine misuse in clinical practice? Ther Adv Drug Saf. 2025;16. doi:10.1177/20420986241310685.Google Scholar
Langreck, CB, Chen, BK, Luna, VM, Nelson, M, Turi, G, Hill, R, et al. Mu opioid receptor activation is required for NMDA receptor antagonist effects on stress-induced maladaptive behavior. Biol Psychiatry. 2025; doi:10.1016/j.biopsych.2025.07.004.Google Scholar
Little, HJ, Alexander, KL, Gargan, MF, Widdison, AL. Ketamine and the Guinea-pig ileum: possible opiate agonist and antagonist actions and effects of peptidase inhibition. J Pharmacol Exp Ther. 1983;225(1):206–12. doi:10.1016/s0022-3565(25)33573-1.Google Scholar
Zhang, F, Hillhouse, TM, Anderson, PM, Koppenhaver, PO, Kegen, TN, Manicka, SG, et al. Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice. Pharmacol Biochem Behav. 2021;208:173228 doi:10.1016/j.pbb.2021.173228.Google Scholar
Wulf, HA, Browne, CA, Zarate, CA, Lucki, I. Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors. Psychopharmacology. 2022;239(7):2309–16. doi:10.1007/s00213-022-06118-4.Google Scholar
Moretti, M, Ribeiro, CM, Neis, VB, Bettio, LE, Rosa, PB, Rodrigues, AL. Evidence for the involvement of opioid system in the antidepressant-like effect of ascorbic acid. Naunyn Schmiedeberg’s Arch Pharmacol. 2017;391(2):169–76. doi:10.1007/s00210-017-1446-4.Google Scholar
Malikowska-Racia, N, Golebiowska, J, Nikiforuk, A, Khoo, SY-S, Popik, P. Effects of ketamine optical isomers, fluoxetine and naloxone on timing in differential reinforcement of low-rate response (DRL) 72-s task in rats. Eur Neuropsychopharmacol. 2023;67:37–52. doi:10.1016/j.euroneuro.2022.11.007.Google Scholar
Jiang, C, DiLeone, RJ, Pittenger, C, Duman, RS. The endogenous opioid system in the medial prefrontal cortex mediates ketamine’s antidepressant-like actions. Transl Psychiatry. 2024;14(1). doi:10.1038/s41398-024-02796-0.Google Scholar
Gomes, I, Gupta, A, Margolis, EB, Fricker, LD, Devi, LA. Ketamine and major ketamine metabolites function as allosteric modulators of opioid receptors. Mol Pharmacol. 2024;106(5):240–52. doi:10.1124/molpharm.124.000947.Google Scholar
Di Ianni, T, Ewbank, SN, Levinstein, MR, Azadian, MM, Budinich, RC, Michaelides, M, et al. Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats. Nat Commun. 2024;15(1): doi:10.1038/s41467-024-45157-7.Google Scholar
Aguilar, AG, Beauregard, BA, Conroy, CP, Khatiwoda, YT, Horsford, SM, Nichols, SD, et al. Pronounced regional variation in esketamine and ketamine prescribing to US Medicaid patients. J Psychoactive Drugs. 2023;56(1):33–9. doi:10.1080/02791072.2023.2178558.Google Scholar
Vekhova, KA, Namiot, ED, Jonsson, J, Schiöth, HB. Ketamine and Esketamine in clinical trials: fda‐approved and emerging indications, trial trends with putative mechanistic explanations. Clin Pharmacol Ther. 2024;117(2):374–86. doi:10.1002/cpt.3478.Google Scholar
Figure 0

Table 1. Eligibility criteria

Figure 1

Table 2. Characteristics of clinical studies investigating the potential mediating effect of the opioid system on antidepressant efficacy of ketamine or esketamine in persons with depressive disorders (n = 12)

Figure 2

Table 3. Characteristics of preclinical studies investigating the potential mediating effect of the opioid system on behavioral outcomes of ketamine in depressed animal models (n = 4)

Figure 3

Figure 1. PRISMA flow diagram of literature search.Source: Page MJ, et al. BMJ 2021;372:n71. doi: 10.1136/bmj.n71 [28].

Supplementary material: File

Lu et al. supplementary material

Lu et al. supplementary material
Download Lu et al. supplementary material(File)
File 1.9 MB
Submit a response

Comments

No Comments have been published for this article.